hero-galleri.jpg

The #1 employee-ranked health benefit* is now available from US Wellness!

US Wellness has partnered with  GRAIL to offer Galleri®, the first-of-its-kind multi-cancer early detection blood test.†

*Study demographics included 1,000 respondents who were full-time employees working at companies withat least 3000 employees: 15% of sample aged 65+, 70% of sample aged 50-64; 15% aged under 50 with cancer risk factors. Respondents were a representative mix across gender, region, race, ethnicity. Ipsos Market Research 2022. GRAIL, Inc. Data on file: GA-2023-0102

† The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

Late-stage cancer costs 3X more on average to treat vs early-stage cancer.¹

The Galleri multi-cancer early detection test screens for a signal shared by more than 50 types of cancer, many of which are not commonly screened for today.² With a simple blood draw, the Galleri test can provide your employees an additional screening option that can help them be proactive about their health.

Together with GRAIL, Inc., US Wellness is giving employees more control when it comes to cancer. Employees say the Galleri test is their #1 ranked health benefit, as important as a $1,000 salary increase.*

*Study demographics included 1,000 respondents who were full-time employees working at companies with at least 3000 employees: 15% of sample aged 65+, 70% of sample aged 50-64; 15% aged under 50 with cancer risk factors. Respondents were a representative mix across gender, region, race, ethnicity. Ipsos Market Research 2022. GRAIL, Inc. Data on file: GA-2023-0102
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri should be used in addition to healthcare provider recommended screening tests.
galleri-graph-1105.png
*Usual care represents real-world cancer diagnostic processes including screening, incidental detection, and symptomatic workup.
**Modeled data of early version of Galleri added to usual care in elevated risk population age 50–79 years. Detectable cancers represent 68%. Results based on performance data from Liu, et al. Ann Oncol. 2020 modeled with stage-specific incidence and survival of all invasive cancers diagnosed in persons aged 50–79 between 2006 and 2015 from the US Surveillance, Epidemiology, and End Results (SEER) program. State-transition (interception) model depicts adding early version of Galleri test to usual care. Assumes long-term screening results with optimized screening interval.

Galleri screens for a signal shared by more than 50 types of cancer.²

The process is simple…

computer.png

Request A Test Online

which is reviewed and approved by a independent telemedicine provider, if appropriate

blood-draw-3.png

Blood Draw Conducted

in a partner lab, onsite event, or at home

email-7.png

Results Returned to Provider

and shared with employee

comments.png

Support Services for Positive Test Results

for you and your primary care provider

Treating cancer starts with knowing you have it. US Wellness is proud to bring you the Galleri test to give you more control when it comes to cancer.

Important Safety Information:

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory / Test Information:

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes. 

 

1 Reddy SR, et al. Cost of cancer management by stage at diagnosis among Medicare beneficiaries. Curr Med Res Opin. 2022;38(8):1285-1294. doi: 10.1080/03007995.2022.2047536.

2 Klein EA, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177. doi: 10.1016/j.annonc.2021.05.806.

3 Hubbell E, et al. Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiol Biomarkers Prev. 2021;30(3):460-468. doi: 10.1158/1055-9965.EPI-20-1134.